EUCTR2020-001060-28-DK进行中（未招募）1 期
Documentation of efficacy for intralymphatic allergen immunotherapy in a phase III randomized, parallel group, double blind placebo-controlled multisite field trial - ILIT.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 528
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients have seasonal grass pollen induced rhino conjunctivitis during the two most recent seasons and a positive skin prick test resulting in a wheal diameter = 3 mm to ALK Soluprick Grass 225. The latter is important as it predicts that the patients IgE recognises allergens found in ALKs preparation for treatment, a crucial condition for treatment success.
- •Patients are adults; more than 18 years old on the day of first treatment,
- •Patients must be comfortable with digital data entry and have accepted and digitally approved the informed consent document.
- •Patient have to have sufficient symptoms during the grass pollen season to allow us to record an effect of the treatment; we will evaluate question 1 – 6 and 18 – 22 of their RHINE III and the sum of the retrospective RTSS questionnaires from the pre-screening tools to assess the severity of grass pollen dependent rhinoconjunctivitis and to identify or predict possible grass pollen dependent asthma affecting patients. For inclusion, patients have to have a retrospective RTSS score >7 on a scale of 0 – 18 (most severe). We will select patients with the highest RTSS score.
- •90% of patients included for the baseline year will be included in the treatment study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •1 previous allergen immunotherapy for grass pollen allergy
- •2 Significant allergic sensitisation to mugwort (Artemisia vulgaris) or sensitisation with persistent exposure to pet animal allergens that results in allergic symptoms
- •3 Known or suspected allergy to additives to the study product; allergy to aluminium hydroxide or phenol
- •4 Depot steroid injection for treatment of allergic rhinoconjunctivitis
- •5 Upper airway disease (non-allergic sinusitis, nasal polyps)
- •6 uncontrolled asthma or severe asthma with post bronchodilator FEV1<70% of expected, decided by the investigator
- •7 Pulmonary disease, perennial or seasonal with daily use of more than 800 microgram inhaled budesonide/ day (or equivalent) or treatment with omalizumab or other biologics for allergy or asthma.
- •8 Pulmonary disease with post bronchodilator FEV1 < 70 % of predicted
- •9 Allergic reaction within the last 4 days or anaphylaxis last month before ILIT injections
- •10 severe Autoimmune or collagen disease
- •11 Disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension and treatment with beta-blockers)
- •12 Known cardiovascular disease, i.e. not even NYHA class I.
- •13 Use of ACE-blockers. If ACE-blockers are used, they should be withdrawn after discussion with the Principal Investigator 2 weeks before first injection and until after the last injection
- •14 Recent or on-going hepatic or renal disease
- •15 All malignant diseases
- •16 Immuno- or chemotherapy during the last 15 years,
- •17 Increased bleeding tendency
- •18 Any other than study medication with an effect of interfering with the immune response
- •19 Chronic obstructive or restrictive lung disease
- •20 Skin diseases with barrier defect in the inguinal areas
- •21 Alcohol or drug abuse
- •22 Participation in another clinical study from visit 1-8.
研究者
相似试验
已完成
1 期
Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen ExtractRhinitis, Allergic, SeasonalAllergic Rhinitis Due to Grass PollenAllergic, With Asthma RhinitisAllergic AsthmaAllergic RhinitisNCT05297760University of Zurich60
已完成
2 期
Effects of Intralymphatic Allergen Immunotherapy in treatment of allergic rhinitisIRCT20161206031256N2Vice chancellor for research, Mashhad University of Medical Sciences15
终止
不适用
The efficacy and adverse effect of intralymphatic immunotherapy (ILIT) for allergic diseasesDiseases of th respiratory systemKCT0001534Gachon University Gil Medical Center144
招募中
不适用
Intralymphatic immunotherapy with Tyrosine S®, allergen extract for immunotherapyDiseases of th respiratory systemKCT0001777Gachon University40
已完成
3 期
Documentation of Efficacy of Intralymphatic Allergen ImmunotherapyAllergic Rhinitis Due to Grass PollenAllergic Conjunctivitis of Both EyesAllergic AsthmaNCT05191186Aarhus University Hospital450